2024
Low skeletal muscle mass and treatment outcomes among adults with haematologic malignancies: A systematic review and meta‐analysis
Anabtawi N, Pasala M, Grimshaw A, Kharel P, Bal S, Godby K, Siwakoti A, Buford T, Bhatia S, Costa L, Williams G, Giri S. Low skeletal muscle mass and treatment outcomes among adults with haematologic malignancies: A systematic review and meta‐analysis. Journal Of Cachexia Sarcopenia And Muscle 2024, 15: 1084-1093. PMID: 38558541, PMCID: PMC11154774, DOI: 10.1002/jcsm.13446.Peer-Reviewed Original ResearchConceptsLow skeletal muscle massNon-relapse mortalityProgression free survivalTreatment-related toxicityHaematological malignanciesOverall survivalSkeletal muscle massMuscle massEffects of low skeletal muscle massImpact of low skeletal muscle massIncreased risk of treatment-related toxicityPresence of low skeletal muscle massRisk of treatment-related toxicityHazard ratioAssociated with worse survival outcomesAssociated with worse OSDerSimonian-Laird random-effects modelModerate heterogeneityInferior overall survivalWorse survival outcomesConfidence intervalsRandom-effects modelFree survivalSolid malignanciesPre-published protocol
2022
Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review
Grant SJ, Grimshaw AA, Silberstein J, Murdaugh D, Wildes TM, Rosko AE, Giri S. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review. Transplantation And Cellular Therapy 2022, 28: 294-302. PMID: 35288347, PMCID: PMC9197870, DOI: 10.1016/j.jtct.2022.03.006.Peer-Reviewed Original ResearchConceptsImmune effector cell-associated neurotoxicity syndromeCAR T-cell therapyT-cell therapyLong-term outcomesHematologic malignanciesCell therapyClinical presentationLymphocytic leukemiaCAR-T cell therapy recipientsChimeric antigen receptor T-cell therapyJoanna Briggs Institute critical appraisal toolsDiffuse large B-cell lymphomaCAR T-cell productsLarge B-cell lymphomaCytokine release syndromeRefractory hematologic malignanciesLong-term sequelaeSubset of patientsC-reactive proteinCommon hematologic malignancyLife-threatening conditionNon-Hodgkin lymphomaCross-trial comparisonsAcute lymphocytic leukemiaChronic lymphocytic leukemia